[go: up one dir, main page]

GT199700096A - Ligandos espirociclos de un subtipo de receptor de la dopamina. - Google Patents

Ligandos espirociclos de un subtipo de receptor de la dopamina.

Info

Publication number
GT199700096A
GT199700096A GT199700096A GT199700096A GT199700096A GT 199700096 A GT199700096 A GT 199700096A GT 199700096 A GT199700096 A GT 199700096A GT 199700096 A GT199700096 A GT 199700096A GT 199700096 A GT199700096 A GT 199700096A
Authority
GT
Guatemala
Prior art keywords
receptor subtype
dopamine receptor
spyrocycle
links
compounds
Prior art date
Application number
GT199700096A
Other languages
English (en)
Inventor
Todd William Butler
Anton Franz Joseph Fliri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199700096A publication Critical patent/GT199700096A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS FARMACOLOGICAMENTE ACTIVOS DE TRANSPIPERAZIN1ILESPIRO[CICLOHEXANO1,1'ISOBENZOFURANO] QUE SON LIGADOS DE UN SUBTIPO DE RECEPTOR DE LA DOPAMINA Y QUE TIENEN UNA PREFERENCIA POR EL RECEPTOR D4 DE LA DOPAMINA. ESTOS COMPUESTOS PRESENTAN ACTIVIDAD DOPAMINERGICA CENTRAL, COMO SE DEFINE MAS ADELANTE, Y SON UTILES EN EL TRATAMIENTO Y/O PREVENCION DE TRASTORNOS DEL SISTEMA DE LA DOPAMINA. ESTOS COMPUESTOS TIENEN LA ESTRUCTURA QUIMICA ( I ), EN LA QUE A, B, R1, R2, R3, R4, R5 Y R6 SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
GT199700096A 1996-08-26 1997-08-25 Ligandos espirociclos de un subtipo de receptor de la dopamina. GT199700096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2479796P 1996-08-26 1996-08-26

Publications (1)

Publication Number Publication Date
GT199700096A true GT199700096A (es) 1999-02-16

Family

ID=21822443

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199700096A GT199700096A (es) 1996-08-26 1997-08-25 Ligandos espirociclos de un subtipo de receptor de la dopamina.

Country Status (22)

Country Link
US (1) US6664258B1 (es)
EP (1) EP0925291B1 (es)
JP (1) JP3152941B2 (es)
AP (1) AP9701075A0 (es)
AR (1) AR013836A1 (es)
AT (1) ATE311377T1 (es)
AU (1) AU3632297A (es)
CA (1) CA2264549C (es)
CO (1) CO4560554A1 (es)
DE (1) DE69734774D1 (es)
GT (1) GT199700096A (es)
HN (1) HN1997000117A (es)
HR (1) HRP970455A2 (es)
ID (1) ID18076A (es)
IL (1) IL128050A0 (es)
IS (1) IS4969A (es)
MA (1) MA26437A1 (es)
PA (1) PA8436501A1 (es)
PE (1) PE108498A1 (es)
TN (1) TNSN97143A1 (es)
WO (1) WO1998008835A1 (es)
ZA (1) ZA977597B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
BR9914018A (pt) * 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
GB0328906D0 (en) 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
WO2013072705A1 (en) 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758919A (fr) 1969-11-15 1971-05-13 Merck Patent Gmbh Spiro-composes
US4025558A (en) 1974-04-12 1977-05-24 The Upjohn Company Organic compounds
US3932425A (en) 1974-04-12 1976-01-13 The Upjohn Company Benzospiran derivatives
US4010201A (en) 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
DE2818329A1 (de) 1978-04-26 1979-11-08 Yoshitomi Pharmaceutical Spiro eckige klammer auf cyclohexan- 1,9'-thioxanthen eckige klammer zu -verbindungen
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
ATE182139T1 (de) 1992-10-23 1999-07-15 Merck Sharp & Dohme Dopamin rezeptor subtyp liganden
GB9317631D0 (en) 1993-08-25 1993-10-13 Bxl Plastics Ltd Multi-layered composite
US5403846A (en) 1993-11-22 1995-04-04 Merck & Co., Inc. Spirocycles
AU691296B2 (en) * 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
GB9410031D0 (en) 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
IS4969A (is) 1999-02-05
JP2000502360A (ja) 2000-02-29
JP3152941B2 (ja) 2001-04-03
PE108498A1 (es) 1999-01-29
ZA977597B (en) 1999-02-25
HN1997000117A (es) 1997-12-26
WO1998008835A1 (en) 1998-03-05
CO4560554A1 (es) 1998-02-10
AP9701075A0 (en) 1997-10-31
CA2264549C (en) 2004-09-14
ID18076A (id) 1998-02-26
PA8436501A1 (es) 2000-05-24
MA26437A1 (fr) 2004-12-20
IL128050A0 (en) 1999-11-30
EP0925291A1 (en) 1999-06-30
AU3632297A (en) 1998-03-19
TNSN97143A1 (fr) 2005-03-15
AR013836A1 (es) 2001-01-31
HRP970455A2 (en) 1998-08-31
DE69734774D1 (de) 2006-01-05
EP0925291B1 (en) 2005-11-30
CA2264549A1 (en) 1998-03-05
ATE311377T1 (de) 2005-12-15
US6664258B1 (en) 2003-12-16

Similar Documents

Publication Publication Date Title
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
PA8521501A1 (es) Ligandos para receptores de melanocortina
GT199700096A (es) Ligandos espirociclos de un subtipo de receptor de la dopamina.
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
FI113767B (fi) Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
AR028705A1 (es) Bis-arilsulfonas
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
AR032641A1 (es) Agonista de subtipo de receptor 5-ht 1a.
ES2132401T3 (es) Tetrahidro-1h-benzazepinonas y hexahidroazepinonas como antagonistas selectivos del receptor colecistoquinina-b.
MX9700959A (es) Derivados de becimidazol que tienen actividad dopaminergica.
GT199800135A (es) 2 - aminopiridinas con sustituyentes alcoxi ramificados.
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
ES2122253T3 (es) Derivados (arilalcoxibencil)aminopropanamidicos sustituidos, su preparacion y su utilizacion como agentes antiepilepticos, neuroprotectores y antidepresivos.
NO176097C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte cykloheksener
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
ES2160240T3 (es) Benzamidas para el tratamiento de desordenes neurodegenerativos.
PE26198A1 (es) Compuestos farmaceuticos
ECSP972235A (es) Ligandos espirociclicos de un subtipo de receptor de la dopamina
DE60135675D1 (de) Behandlung von motorischen veränderungen mit 5-hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen
ECSP951500A (es) Derivados de bencimidazol
ES2183843T3 (es) Compuestos triciclicos que tienen afinidad por el receptor 5-ht1a.